KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its price target lowered by analysts at HC Wainwright from $24.00 to $20.00. They now have a "buy" rating on the stock.
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock.
KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year [Yahoo! Finance]
KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year